Following a Federal Court decision, the Swiss Federal Office of Public Health will resume its process of holding drug reviews and systematic price comparisons every three years for drugs that are reimbursed by statutory health insurance. These reviews may include international price comparisons as well as cost-benefit assessments and comparisons with other medicines. Cost savings of up to 180 million Swiss francs over the next three years are expected to result from these reviews.